HPC
PCRX icon

HM Payson & Co’s Pacira BioSciences PCRX Stock Holding History

HM Payson & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-200
Closed -$15K – 1112
2022
Q1 		$15K Sell
200
-450
-69% -$30K ﹤0.01% 795
2021
Q4 		$39K Sell
650
-600
-48% -$33.1K ﹤0.01% 653
2021
Q3 		$70K Hold
1,250
– – ﹤0.01% 537
2021
Q2 		$76K Buy
1,250
+1,200
+2,400% +$76K ﹤0.01% 524
2021
Q1 		$4K Buy
+50
New +$3.57K ﹤0.01% 978
2020
Q2 		– Sell
-300
Closed -$10K – 911
2020
Q1 		$10K Sell
300
-200
-40% -$8.31K ﹤0.01% 736
2019
Q4 		$23K Hold
500
– – ﹤0.01% 701
2019
Q3 		$19K Sell
500
-400
-44% -$16K ﹤0.01% 738
2019
Q2 		$39K Buy
+900
New +$38.2K ﹤0.01% 638

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

HM Payson & Co's PCRX Position: Q2 2022 in Review

HM Payson & Co sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 200 shares — an estimated $15K sold.

HM Payson & Co first reported a position in PCRX in Q2 2019 and held it in 9 quarters. The position peaked at $76K in Q2 2021. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

  • HM Payson & Co reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
  • HM Payson & Co sold 200 Pacira BioSciences shares in Q2 2022, an estimated $15K.
  • HM Payson & Co first reported a position in Pacira BioSciences in Q2 2019 and held it in 9 quarters.
  • HM Payson & Co's Pacira BioSciences position peaked at $76K in Q2 2021.
  • 284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on HM Payson & Co's 13F filing for Q2 2022, filed 15 Aug 2022.